Objective: To evaluate safety and efficacy of Peg-INF combined with ribavirin for genotype 4 infected children.
Methods: Seven children were included, five were infected parentrally, One vertically and one had both exposures. Clinical and laboratory evaluation were undertaken as well as quantitative PCR for HCV RNA before therapy at, 12, 24 and 52 weeks during treatment and one year after therapy.